Compare ClearPoint Neuro Inc (CLPT) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Palantir Technologies Inc — how do they compare? ClearPoint Neuro Inc trades at $15.83 (market cap $478.63M), while Palantir Technologies Inc trades at $133.95 (market cap $320.57B). The key difference: Palantir Technologies Inc is far larger — about 669.8× ClearPoint Neuro Inc's market cap. Which is the better fit depends on your goals.
| CLPT | PLTR | |
|---|---|---|
Market Cap | $478.63M | $320.57B |
Sector | Health | Technology |
52-Week High | $29.60 | $207.18 |
52-Week Low | $8.66 | $107.27 |
Enterprise Value | $506.63M | $312.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
PLTR trades at $130.05, up 2.57% today, with technical indicators showing neutral signals amid bearish moving averages. The company demonstrates exceptional fundamental strength with 2025 revenue of $4.48B and net income of $1.63B, representing a 36.3% profit margin. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $0.33 surpassing the $0.28 estimate. Analyst consensus remains positive with a $185.75 price target, though valuation metrics remain elevated at P/E of 146.11 and P/S of 63.97.
PLTR presents a growth opportunity with strong AI positioning and expanding profitability, but faces significant valuation risk and competitive pressures. The stock's premium multiples require sustained high growth to justify current levels, while upcoming Q2 2026 earnings on August 3 will be critical for validating the growth trajectory. Institutional sentiment remains divided with 46% buy ratings versus 42% hold recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
